← Map · Health Care Equipment · S&P MidCap 400 · $11.7B · Last Aug 06 AMC
GMED GLOBUS MEDICAL CLASS A
Yes — mid-cap, buys enabling tech
What they are doing
Spine implants + Excelsius robotics + Surgimap planning. On the call, enabling-tech revenue ~26% (lease/rent vs cash sales) while Excelsius placements +25% YoY. 13k+ robotic procedures. SCRIPTS patient-specific implants (~100 day turn) integrate with Excelsius. The 10-K is where they say the robot is a “foundation for future AI,” plus Surgimap, the INR license, and Capstone. Classic buy-the-edge. No AI KPI on the call — placement counts are robot volume.
Why the score
- Reach 3 not 2: robot + planning + patient-specific implants.
- Weight 3 not 4: needle in the spine sale. AI still prospective.
- Proof 3 not 4: robot is in the loop. No planning-accuracy number.
What would move it next quarter: Surgimap/AI planning used in X% of cases, or SCRIPTS + Excelsius vs freehand.
Open these first
Evidence
gmed:NevroMergerAgreementMember 2025-04-03 0001237831 srt:MinimumMember 2025-12-31 0001237831 srt:MaximumMember 2025-12-31 0001237831 gmed:ImagingNavigationAndRoboticsInrDivisionMember 2025-07-01 2025-09-30 0001237831 srt:ScenarioForecastMember gmed:ImagingNavigationAndRoboticsInrDivisionMember 2026-01-01 2026-03-31 000123783 ing the fourth quarter of 2021, the Company acquired Capstone Surgical Technologies, LLC, a company that engages in the business of creating advanced drill and robotic sur
1 gmed:NevroMergerAgreementMember 2026-01-01 2026-06-30 0001237831 gmed:MedicalDeviceTechnologyMember 2026-04-01 2026-06-30 0001237831 gmed:ImagingNavigationAndRoboticsInrDivisionMember 2025-07-01 2025-09-30 0001237831 gmed:ImagingNavigationAndRoboticsInrDivisionMember 2026-01-01 2026-03-31 0001237831 gmed:MedicalDeviceTechnol ts with musculoskeletal disorders. We are primarily focused on implants that promote healing in patients with musculoskeletal disorders, including the use of a robotic gu
The print
Pfeil / Kline on Excelsius placements vs enabling-tech $